Journal
JOURNAL OF ANTIBIOTICS
Volume 74, Issue 6, Pages 421-423Publisher
SPRINGERNATURE
DOI: 10.1038/s41429-021-00414-5
Keywords
-
Funding
- Canadian Institute for Health Research
- Swiss National Fund [40AR40_180205/1]
- Swedish Research Council [2017-05973]
- Major Innovation Fund program of the Ministry of Jobs, Economy and Innovation, Government of Alberta through the AMR -One Health Consortium
- Swiss National Science Foundation (SNF) [40AR40_180205] Funding Source: Swiss National Science Foundation (SNF)
- Swedish Research Council [2017-05973] Funding Source: Swedish Research Council
Ask authors/readers for more resources
The average sales of new antibiotics during their first 8 years on the market are inadequate to cover costs of supplying the products, with a striking reliance on the US market accounting for 84% of sales. Additional revenues, especially from other countries, are needed to support incentives for the development of new antibiotics, with market entry rewards potentially being of particular value.
We calculate the average sales of new antibiotics during their first 8 years on the market. The discounted net present value is only $240 m in total per antibiotic, well below costs of supplying these products. The reliance on the US for sales is striking: the US market accounts for 84% of sales during the first 8 years. These facts clarify the need for additional revenues, especially from other countries, to support incentives for the development of new antibiotics. Market entry rewards may be of particular value.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
